Atlas Trials

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

Clinical trial NCT04251416 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04251416
Sponsor
Yale University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Endometrial Carcinoma
Start date
2020-03-17
Primary completion
2026-12-01
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.